Amalgamated Financial’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Amalgamated Financial’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3K	Buy	+150	New	+$3.34K	﹤0.01%	2985

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's SGTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2022: 150 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2985 among its holdings.

48 funds tracked by Wall St. Rank hold SGTX as of Q1 2022.

Amalgamated Financial held 150 shares of Sigilon Therapeutics, Inc. Common Stock worth $3K as of Q1 2022.
Sigilon Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Sigilon Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2985 holding.
48 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.